SEARCH

SEARCH BY CITATION

References

  • 1
    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321328.
  • 2
    Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257260.
  • 3
    Goetze JP, Christoffersen C, Perko M, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17:11051107.
  • 4
    Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509516.
  • 5
    Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:29132918.
  • 6
    De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:10141021.
  • 7
    Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655663.
  • 8
    Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation. 1996;93:19631969.
  • 9
    Arakawa N, Nakamura M, Aoki H, et al. Plasma brain natriuretic peptide predicts survival after acute myocardial infarction. J Am Coll Cardiol. 1996;27:16561661.
  • 10
    Omland T, De Lemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol. 2002;89:463465.
  • 11
    Sabatine MS, Morrow DA, De Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:17601763.
  • 12
    Mega JL, Morrow DA, De Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335339.
  • 13
    Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J. 2005;26:241249.
  • 14
    Muller-Bardorff M, Hallermayer K, Schroder A, et al. Improved troponin T ELISA specific for cardiac troponin T isoform: assay development and analytical and clinical validation. Clin Chem. 1997;43:458466.
  • 15
    Cotton F, Thiry P, Hsain AB, et al. Analyzer transfer of a broad range high-sensitivity C-reactive protein immunoassay. Clin Lab. 2001;47:405409.
  • 16
    Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation. 1999;100:96102.
  • 17
    Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy (Thrombolysis in Myocardial Infarction). J Am Coll Cardiol. 1998;31:14601465.
  • 18
    Festa A, D’Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:4247.
  • 19
    Kondo N, Nomura M, Nakaya Y, et al. Association of inflammatory marker and highly sensitive C-reactive protein with aerobic exercise capacity, maximum oxygen uptake and insulin resistance in healthy middle-aged volunteers. Circ J. 2005;69:452457.
  • 20
    Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly related to metabolic syndrome in women than in men: the Minoh Study. Circ J. 2005;69:386391.
  • 21
    Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:21652168.
  • 22
    Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 2000;102:10001006.
  • 23
    Arroyo-Espliguero R, Avanzas P, Cosin-Sales J, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J. 2004;25:401408.
  • 24
    Wiese S, Breyer T, Dragu A, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000;102:30743079.
  • 25
    Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195203.
  • 26
    Talwar S, Squire IB, Downie PF, et al. Plasma N terminal pro-brain natriuretic peptide and cardiotrophin 1 are raised in unstable angina. Heart. 2000;84:421424.
  • 27
    Horio T, Shimada K, Kohno M, et al. Serial changes in atrial and brain natriuretic peptides in patients with acute myocardial infarction treated with early coronary angioplasty. Am Heart J. 1993;126:293299.
  • 28
    Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:19211929.
  • 29
    Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction: the Christchurch Cardioendocrine Research Group. Heart. 1999;81:114120.
  • 30
    Morrow DA, De Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIM1 18. J m Coll Cardiol. 2002;41:12641272.
  • 31
    Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:19091916.
  • 32
    Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined–a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959969.
  • 33
    Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guidelines update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2002;40:13661374.
  • 34
    Gill D, Seidler T, Troughton RW, et al. Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Clin Sci (Lond). 2004;106:135139.
  • 35
    Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation. 1993;88:8291.
  • 36
    Jernberg T, Stridsberg M, Venge P, et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40:437445.
  • 37
    Bjorklund E, Jernberg T, Johanson P, et al. Admission NT-proBNP and its interaction with admission troponin T and ST-segment resolution for early risk stratification in ST-elevation myocardial infarction. Heart. 2006;92(6):735740.
  • 38
    James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO) IV substudy. Circulation. 2003;108:275281.
  • 39
    FRISC-2 investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708715.
  • 40
    Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail. 2004;6:327333.
  • 41
    Galvani M, Ottani F, Oltrona L, et al. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation. 2004;110:128134.